SCHEMBL3058409

SCHEMBL3058409

CN1CCN(C2CCN(C(=O)c3nc4c(C(F)(F)F)cc(-c5ccoc5)cn4c3Cl)CC2)C1=O

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SYK P43405 2/20 0.37
TYRO3 Q06418 2/20 0.35
MERTK Q12866 2/20 0.35
TRPV1 Q8NER1 1/20 0.33
NPY5R Q15761 1/20 0.32
HDAC4 P56524 1/20 0.31
BTK Q06187 3/20 0.31
RBP4 P02753 2/20 0.31
P2RX7 Q99572 1/20 0.31
F10 P00742 1/20 0.31
SCD5 Q86SK9 1/20 0.31
EPHX2 P34913 1/20 0.31
FGFR3 P22607 1/20 0.30
HSD11B1 P28845 1/20 0.30
LMNA P02545 1/20 0.30
MCHR1 Q99705 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3063651 0.87 F10 (0.34) TYRO3MERTKTRPV1NPY5RRBP4
SCHEMBL3057907 0.87 F10 (0.36) TYRO3MERTKTRPV1NPY5RRBP4
SCHEMBL3058447 0.87 IRAK4 (0.36) SYKTYRO3MERTKTRPV1RBP4
SCHEMBL3076897 0.86 VNN1 (0.37) TYRO3MERTKTRPV1NPY5RHDAC4
SCHEMBL3075353 0.86 VNN1 (0.37) TYRO3MERTKTRPV1NPY5RHDAC4
SCHEMBL3069559 0.86 TRPV1 (0.33) TYRO3MERTKTRPV1HDAC4RBP4
SCHEMBL3785019 0.86 ENPP2 (0.37) SYKTYRO3MERTKTRPV1NPY5R
SCHEMBL3064728 0.85 TRPV1 (0.35) TYRO3MERTKTRPV1HDAC4RBP4
SCHEMBL3061568 0.85 MCHR1 (0.33) TYRO3MERTKTRPV1HDAC4MCHR1
SCHEMBL3791014 0.85 L3MBTL3 (0.39) TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100272680-A1 Piperidinyl Cyclic Amido Antiviral Agents BASKARAN SUBRAMANIAN 2010-10-28 US claimed
WO-2010091411-A1 PIPERIDINYL CYCLIC AMIDO ANTIVIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2010-08-12 WO claimed
US-20100272680-A1 Piperidinyl Cyclic Amido Antiviral Agents BASKARAN SUBRAMANIAN 2010-10-28 US disclosed
US-20100272680-A1 Piperidinyl Cyclic Amido Antiviral Agents BASKARAN SUBRAMANIAN 2010-10-28 US disclosed
WO-2010091411-A1 PIPERIDINYL CYCLIC AMIDO ANTIVIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2010-08-12 WO disclosed
WO-2010091411-A1 PIPERIDINYL CYCLIC AMIDO ANTIVIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100272680-A1 Piperidinyl Cyclic Amido Antiviral Agents ZC3HAV1, MAVS, EIF2AK2 SYK 4623/4885TYRO3 3671/4885MERTK 2693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.